Posts tagged common stock
OPKO completes acquisition of Transition Therapeutics

OPKO Health (NASDAQ:OPK) has completed the acquisition of Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) by way of a plan of arrangement.

Under the transaction, shareholders of Transition will receive about 6.4 million shares of OPKO common stock, or 0.1657 shares of OPKO for each common share of Transition.

Read More
Leerink downgrades Imprivata to market perform

Leerink downgraded Imprivata (NYSE:IMPR) to “market perform” but upped its price target to $19.25 from $17 after the company entered into a definitive agreement to be acquired by an affiliate of Thoma Bravo, LLC, a private equity investment firm. The stock closed at $19.01 on Wednesday.

Shareholders will receive $19.25 in cash per share of Imprivata common stock, which is a 33% premium to Tuesday’s closing price of $14.50.

Read More
QLT and Aegerion Pharma to merge

QLT (NASDAQ:QLTI; TSX:QLT) and Aegerion Pharmaceuticals (NASDAQ:AEGR) have entered into a definitive merger agreement, with the resulting company to be renamed, Novelion Therapeutics.

Under the accord, each outstanding share of Aegerion common stock will be exchanged for 1.0256 shares of QLT common stock.

Read More
ContraVir Pharma to merge with Ciclofilin Pharma

ContraVir Pharmaceuticals (NASDAQ:CTRV) has entered into a definitive merger agreement with closely-held Ciclofilin Pharmaceuticals.

Under the accord, ContraVir will acquire all of the outstanding equity interests in Ciclofilin for the right to receive future milestone payments, which will be allocated among the holders of Ciclofilin common stock.

Read More
TearLab prices $17.3-million registered public offering

TearLab (NASDAQ:TEAR; TSX:TLB) has priced a public offering of common stock to raised gross proceeds of approximately $17.3-million to close on May 9.

The offering was priced at 75 cents a share of common stock, or common stock equivalent, with each share of common stock coupled with a warrant to purchase one-half of one share of common stock.

Read More
GeneNews provides financing update

GeneNews (TSX:GEN) has closed the first tranche of a private placement, consisting of the issuance of approximately 5.6 million common shares at a price of 10 cents each, for gross proceeds of approximately $560,000, to be used for working capital.

The company also has executed a term sheet with Alumina Partners for a second tranche, allowing GeneNews to draw down on $10-million (US) in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period.

Read More